bioMérieux announces that its Vitek Reveal antibiotic susceptibility testing system, providing results directly from positive blood cultures, has received 510(k) clearance from the US Food and Drug Administration (FDA).

This instrument, developed by the US company Specific Diagnostics which the group acquired in 2022, complements bioMérieux's unique and comprehensive offering in the fight against bloodstream infections and sepsis.

This modular system directly provides an actionable antibiotic susceptibility test for Gram-negative bacteria, enabling same-day therapeutic decision-making for patients suffering from bacteremic sepsis.

Copyright (c) 2024 CercleFinance.com. All rights reserved.